Posted on 1 SEP 2011: Adelaide, South Australia (September 1, 2011) – vivoPharm is pleased to announce a strategic alliance with MPI Research, the largest single-site preclinical contract research organization (CRO) worldwide.
This exclusive agreement joins more than 60 characterized cell lines and specialty oncology models developed by vivoPharm with the oncology models and molecular imaging programs developed by MPI Research. Sponsors of vivoPharm will be able to access the broad range of discovery, preclinical development, and analytical/bioanalytical services provided by MPI Research. In addition to these combined technical capabilities, the alliance between MPI Research and vivoPharm creates a unique Oncology offering, with experience and capabilities to assist Sponsors in early-stage discovery programs through to clinical development and regulatory strategy.
Ralf Brandt, PhD, Chief Executive Officer of vivoPharm, adds, “We are pleased to align with MPI Research as our partner in the oncology, discovery and overall toxicology space. We are excited and enthusiastic about the potential for the future”.
Glenn J Smits, PhD, Vice President of the Discovery Center at MPI Research states, “MPI Research and vivoPharm share a mutual philosophy for continuous development of scientific expertise and a consultative approach with their Sponsors. This partnership allows MPI Research to not only enhance our laboratory capabilities and oncology models but also our overall oncology drug development program management”.
About MPI Research: MPI Research, with global headquarters in Mattawan, Michigan, provides discovery, preclinical safety, bioanalytical, and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world.
About vivoPharm: vivoPharm is a CRO that offers integrated preclinical services to the biotechnology and pharmaceutical industries. The company’s varied portfolio of services includes in vitro and in vivo efficacy, safety, toxicology (GLP), pharmacodynamic and pharmacokinetic analyses. vivoPharm specializes in highly predictive in vivo orthotopic and metastatic xenograft models.The company’s advanced vivarium facilities, laboratories and corporate headquarters are located in Adelaide, Australia. vivoPharm will open its American laboratory and vivarium facility in Hershey, Pennsylvania in September 2011. The company’s global facilities are complemented by a European sales and project support office based in Munich, Germany. vivoPharm operations are GLP compliant and meet the highest industrial standards.